The molecular docking results indicated that FDX1 and DLAT might be potential drug targets for mitotane, adicicol and dihydrolipoic acid against ccRCC by inducing cuproptosis. The gene discussed is DLAT; the disease is nonpapillary renal cell carcinoma.